SP0190 Juvenile Dermatomyositis: Whats New in 2014?

SP0190 Juvenile Dermatomyositis: Whats New in 2014?

It is increasingly clear that juvenile dermatomyositis (JDM), a rare complex autoimmune disorder that involves autoimmune, vascular and inflammatory mechanisms, is not homogeneous. Rather, the diagnosis of JDM covers a heterogeneous group of patients, with a wide spectrum of outcomes ranging from co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.50
1. Verfasser: Wedderburn, L.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 2
container_start_page 50
container_title Annals of the rheumatic diseases
container_volume 73
creator Wedderburn, L.
description It is increasingly clear that juvenile dermatomyositis (JDM), a rare complex autoimmune disorder that involves autoimmune, vascular and inflammatory mechanisms, is not homogeneous. Rather, the diagnosis of JDM covers a heterogeneous group of patients, with a wide spectrum of outcomes ranging from complete remission through to those with recalcitrant difficult to treat disease, with ongoing active skin rash, calcinosis or vasculopathic complications. In this talk we will consider novel biomarkers that can distinguish these subphenotypes, and the underlying genetics or mechanistic pathways that may drive these disease types. We will also review methods with which to assess and monitor disease and international efforts to standardize the data and samples that are considered minimal to allow the optimal management of patients with JDM. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.6355
doi_str_mv 10.1136/annrheumdis-2014-eular.6355
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777972413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008704311</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1273-7fa4a569c99b017d5bd66d560546cb73e3972e9ff84717e480a00917417d717e3</originalsourceid><addsrcrecordid>eNqVkM1Kw0AUhQdRsFbfIdB16r2dv4wuRGr9o6ig4nKYJBOa0iR1JlG6c-OL-iROrAu3ri73cL57uIeQEcIYkYpjU9duYbsqL308AWSx7VbGjQXlfIcMkIkkyAJ2yQAAaMyUkPvkwPtlWCHBZED44wOggq-Pz9vuzdblykYX1lWmbapN48u29CfRy8K0Prqz71FZR33M2SHZK8zK26PfOSTPl7On6XU8v7-6mZ7P4xQnksayMMxwoTKlUkCZ8zQXIucCOBNZKqmlSk6sKoqESZSWJWAAFEoWvL1Ah2S0vbt2zWtnfauXTefqEKlRShlohjS4TreuzDXeO1votSsr4zYaQfc96T896f4B_dOT7nsKtNjSabX8F_gNfB5xPQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777972413</pqid></control><display><type>article</type><title>SP0190 Juvenile Dermatomyositis: Whats New in 2014?</title><source>BMJ Journals - NESLi2</source><creator>Wedderburn, L.</creator><creatorcontrib>Wedderburn, L.</creatorcontrib><description>It is increasingly clear that juvenile dermatomyositis (JDM), a rare complex autoimmune disorder that involves autoimmune, vascular and inflammatory mechanisms, is not homogeneous. Rather, the diagnosis of JDM covers a heterogeneous group of patients, with a wide spectrum of outcomes ranging from complete remission through to those with recalcitrant difficult to treat disease, with ongoing active skin rash, calcinosis or vasculopathic complications. In this talk we will consider novel biomarkers that can distinguish these subphenotypes, and the underlying genetics or mechanistic pathways that may drive these disease types. We will also review methods with which to assess and monitor disease and international efforts to standardize the data and samples that are considered minimal to allow the optimal management of patients with JDM. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.6355</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2014-eular.6355</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.50</ispartof><rights>2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2014 (c) 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/73/Suppl_2/50.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/73/Suppl_2/50.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Wedderburn, L.</creatorcontrib><title>SP0190 Juvenile Dermatomyositis: Whats New in 2014?</title><title>Annals of the rheumatic diseases</title><description>It is increasingly clear that juvenile dermatomyositis (JDM), a rare complex autoimmune disorder that involves autoimmune, vascular and inflammatory mechanisms, is not homogeneous. Rather, the diagnosis of JDM covers a heterogeneous group of patients, with a wide spectrum of outcomes ranging from complete remission through to those with recalcitrant difficult to treat disease, with ongoing active skin rash, calcinosis or vasculopathic complications. In this talk we will consider novel biomarkers that can distinguish these subphenotypes, and the underlying genetics or mechanistic pathways that may drive these disease types. We will also review methods with which to assess and monitor disease and international efforts to standardize the data and samples that are considered minimal to allow the optimal management of patients with JDM. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.6355</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkM1Kw0AUhQdRsFbfIdB16r2dv4wuRGr9o6ig4nKYJBOa0iR1JlG6c-OL-iROrAu3ri73cL57uIeQEcIYkYpjU9duYbsqL308AWSx7VbGjQXlfIcMkIkkyAJ2yQAAaMyUkPvkwPtlWCHBZED44wOggq-Pz9vuzdblykYX1lWmbapN48u29CfRy8K0Prqz71FZR33M2SHZK8zK26PfOSTPl7On6XU8v7-6mZ7P4xQnksayMMxwoTKlUkCZ8zQXIucCOBNZKqmlSk6sKoqESZSWJWAAFEoWvL1Ah2S0vbt2zWtnfauXTefqEKlRShlohjS4TreuzDXeO1votSsr4zYaQfc96T896f4B_dOT7nsKtNjSabX8F_gNfB5xPQ</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Wedderburn, L.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201406</creationdate><title>SP0190 Juvenile Dermatomyositis: Whats New in 2014?</title><author>Wedderburn, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1273-7fa4a569c99b017d5bd66d560546cb73e3972e9ff84717e480a00917417d717e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wedderburn, L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wedderburn, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SP0190 Juvenile Dermatomyositis: Whats New in 2014?</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2014-06</date><risdate>2014</risdate><volume>73</volume><issue>Suppl 2</issue><spage>50</spage><pages>50-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>It is increasingly clear that juvenile dermatomyositis (JDM), a rare complex autoimmune disorder that involves autoimmune, vascular and inflammatory mechanisms, is not homogeneous. Rather, the diagnosis of JDM covers a heterogeneous group of patients, with a wide spectrum of outcomes ranging from complete remission through to those with recalcitrant difficult to treat disease, with ongoing active skin rash, calcinosis or vasculopathic complications. In this talk we will consider novel biomarkers that can distinguish these subphenotypes, and the underlying genetics or mechanistic pathways that may drive these disease types. We will also review methods with which to assess and monitor disease and international efforts to standardize the data and samples that are considered minimal to allow the optimal management of patients with JDM. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.6355</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2014-eular.6355</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.50
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777972413
source BMJ Journals - NESLi2
title SP0190 Juvenile Dermatomyositis: Whats New in 2014?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T13%3A05%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SP0190%E2%80%85Juvenile%20Dermatomyositis:%20Whats%20New%20in%202014?&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Wedderburn,%20L.&rft.date=2014-06&rft.volume=73&rft.issue=Suppl%202&rft.spage=50&rft.pages=50-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2014-eular.6355&rft_dat=%3Cproquest_cross%3E4008704311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777972413&rft_id=info:pmid/&rfr_iscdi=true